Rasagiline is an irreversible inhibitor of monoamine oxidase used for the symptomatic management of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.
- Mechanism
- Curator reviewed
The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.
- Primary indication
- For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.Curator reviewed · 1 structured indication
- Formula / weight
- C12H13N · 171.2383 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2006 · European Union, 2016
- Code names
- AGN-1135 · TV-1030
- Brand names
Resolves to
RUOKEQAAGRXIBM-GFCCVEGCSA-NSMILESC#CCN[C@@H]1CCC2=CC=CC=C12What you can answer from here — as of September 16, 2026
Which drugs share a target with Rasagiline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account